金吾财讯 | 中泰国际表示,泰德医药(03880)专注于需求广阔的GLP-1等多肽类药物的研发外包服务.来自GLP-1等多肽药物研发与生产外包服务的收入分别占公司2022-24年总收入分别达99.6%、99.9%与99.9%。2024年收入同比增加31.3%,股东净利润同比增加21.0%,资产负债表健康。2024年底进行中的项目较去年同期增加100个至1,549个,期末在手订单总额达约3.5亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.